Page last updated: 2024-12-10

n,n',n'',n'''-tetra(1,2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1,5,10,14-tetraazatetradecane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N,N',N'',N'''-tetra(1,2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1,5,10,14-tetraazatetradecane: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3036117
MeSH IDM0206935

Synonyms (4)

Synonym
n,n',n'',n'''-tetra(1,2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1,5,10,14-tetraazatetradecane
144674-91-9
2-pyridinecarboxamide, n,n'-1,4-butanediylbis(n-(3-(((1,6-dihydro-1-hydroxy-6-oxo-2-pyridinyl)carbonyl)amino)propyl)-1,6-dihydro-1-hydroxy-6-oxo-, tetrasodium salt
DTXSID90162782

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" At a dosage of 30 mumol kg-1, 3,4,3-LIHOPO was less effective owing to the higher retention of Pu in the liver."( The efficacies of 3,4,3-LIHOPO and DTPA for enhancing the excretion of plutonium and americium from the rat: comparison with other siderophore analogues.
Bailly, T; Burgada, R; Ellender, M; Gray, SA; Hodgson, A; Leroux, YG; Moody, JC; Pearce, M; Stradling, GN; Wilson, I, 1992
)
0.28
" The chelating agent was administered at a dosage of 30 mumol."( Efficacy of 3,4,3-LIHOPO for enhancing the excretion of plutonium from rat after simulated wound contamination as a tributyl-n-phosphate complex.
Bailly, T; Burgada, R; Durbin, PW; Fritsch, P; Grillon, G; Metivier, H; Paquet, F; Poncy, JL; Raymond, KN, 1995
)
0.29
"The data obtained after simultaneous injections showed that the ligand dosage effectiveness was not linear and depended on the tissues being considered."( Efficacy of 3,4,3-LIHOPO for reducing neptunium retention in the rat after simulated wound contamination.
Ansoborlo, E; Durbin, PW; Hengé-Napoli, MH; Houpert, P; Montègue, B; Paquet, F; Raymond, KN, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (63.64)18.2507
2000's4 (36.36)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.74 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.22 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]